Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and
Sanofi has agreed to buy cancer drugs firm Synthorx for around $2.5 billion, aiming to strengthen its immune-oncology drug pipeline and creating the possibility of new combination therapies
Takeda’s dengue vaccine has met its target of protection against the disease in children – but there are already concerns about mixed results among different strains of the potentially dead